# IDEAYA Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ideaya-biosciences

- Industry: Pharmaceuticals
- Headquarters: South San Francisco, US
- Website: www.ideayabio.com
- Total disclosed funding: $140M
- Latest round: Series B (Jan 31, 2018)
- Investors on record: 14

## About

IDEAYA Biosciences, Inc., based in the US, focuses on developing precision medicine oncology therapeutics by leveraging synthetic lethality to create targeted treatments for specific cancer patient populations.IDEAYA Biosciences, Inc. specializes in precision medicine for oncology, aiming to create therapeutics that target genetic vulnerabilities in tumors. Founded in 2015 in South San Francisco, US, the company has undergone strategic pivots in its research focus. It has engaged in a total of 6 deals, with its latest funding round being a Private Placement/Follow on amounting to USD 175.00 mn, which matches the total amount raised.IDEAYA Biosciences concentrates on precision medicine oncology therapeutics, primarily utilizing synthetic lethality. Their product pipeline includes drug candidates such as Darovasertib (IDE196), MAT2A (IDE397), and PARG (IDE161), which aim to exploit genetic vulnerabilities in tumors. These offerings are targeted towards specific cancer patient populations identified through molecular diagnostics, with potential applications in global markets.In the most recent year of 2024, IDEAYA Biosciences reported a revenue of USD 7.00 mn, with an EBITDA of USD -307.58 mn. The company generates income through partnerships and collaborations focused on drug development and commercialization, utilizing milestone payments and royalties from its proprietary therapeutic products.IDEAYA Biosciences plans to utilize recent funding to continue advancing its pipeline of oncology therapeutics. The company aims to explore new product launches in the coming years, targeting specific genetic alterations in cancer treatment. Additionally, it may expand into new markets, although specific regions have not been detailed. The exit of Novartis Institute for Biomedical Research from its stake suggests a strategic shift that may influence future partnerships and market positioning.

## Funding rounds

- Series B, Jan 31, 2018, $94M — Canaan Partners, Alexandria Venture Investments, 5AM Ventures, Nextech, GV, Roche Venture Fund, Driehaus Capital Management, BVF Partners, Centene Corporation, 6 Dimensions Capital, Bristol-Myers Squibb Company, Perceptive Advisors, Boxer Capital, 6 Dimensions Capital
- Series A, Feb 29, 2016, $46M — Canaan Partners, Alexandria Venture Investments, 5AM Ventures, 6 Dimensions Capital, Novartis Institute for Biomedical Research, Bristol-Myers Squibb Company

## Investors

- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A, Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A, Series B
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A, Series B
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series A, Series B
- Novartis Institute for Biomedical Research — Series A
- Bristol-Myers Squibb Company — Series A, Series B
- Nextech (https://capitalatlas.ai/funds/nextech) — Series B
- GV (https://capitalatlas.ai/funds/gv) — Series B
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series B
- Driehaus Capital Management (https://capitalatlas.ai/funds/driehaus-capital-management) — Series B
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series B
- Centene Corporation — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series B